{"hands_on_practices": [{"introduction": "A precise description of disease extent is fundamental to clinical pathology, guiding treatment and predicting outcomes. In endometriosis, standardized classification systems like the revised American Society for Reproductive Medicine (r-ASRM) score and the Enzian classification for deep disease are essential tools. This exercise will give you practical experience in applying these detailed scoring systems to a complex, realistic patient case, translating surgical and imaging findings into a formal disease stage and a quantitative fertility prediction. [@problem_id:4319949]", "problem": "A patient aged $32$ years presents with dysmenorrhea and $18$ months of subfertility. Diagnostic laparoscopy and pelvic Magnetic Resonance Imaging (MRI) are performed. Use the following accepted classification systems and epidemiologic modeling framework to compute a quantitative fertility prediction.\n\nFundamental definitions and well-tested rules to be used:\n- Revised American Society for Reproductive Medicine (r-ASRM) classification of endometriosis:\n  - Lesion depth definitions: “superficial” lesions involve the peritoneal surface; “deep” lesions infiltrate $>5$ mm below the peritoneal surface or are endometriotic cysts within the ovary.\n  - Implant scoring (points, per side; sum across all implants):\n    - Peritoneum, superficial: $<1$ cm $\\rightarrow 1$ point, $1$–$3$ cm $\\rightarrow 2$ points, $>3$ cm $\\rightarrow 4$ points.\n    - Peritoneum, deep: $<1$ cm $\\rightarrow 2$ points, $1$–$3$ cm $\\rightarrow 4$ points, $>3$ cm $\\rightarrow 6$ points.\n    - Ovary, superficial: $<1$ cm $\\rightarrow 1$ point, $1$–$3$ cm $\\rightarrow 2$ points, $>3$ cm $\\rightarrow 4$ points.\n    - Ovary, deep (endometrioma): $<1$ cm $\\rightarrow 4$ points, $1$–$3$ cm $\\rightarrow 16$ points, $>3$ cm $\\rightarrow 20$ points.\n  - Adhesion scoring (points, per side; sum across involved structures):\n    - For this case, adnexal adhesions are absent, so adhesion points for ovaries and tubes are $0$.\n    - Posterior cul-de-sac obliteration: partial $\\rightarrow 4$ points; complete $\\rightarrow 40$ points; none $\\rightarrow 0$ points.\n  - r-ASRM staging cutoffs by total points $S$: Stage I (minimal) $1$–$5$, Stage II (mild) $6$–$15$, Stage III (moderate) $16$–$40$, Stage IV (severe) $>40$.\n- Enzian classification for deep endometriosis (compartments and size categories):\n  - Compartment A: vagina and rectovaginal septum.\n  - Compartment B: uterosacral ligaments and pelvic sidewall.\n  - Compartment C: rectum and sigmoid colon (up to $16$ cm from the anal verge).\n  - For each compartment, size grades are: $1$ if $<1$ cm, $2$ if $1$–$3$ cm, $3$ if $>3$ cm; $0$ denotes no lesion in that compartment.\n  - Uterine adenomyosis can be recorded as an additional item; for the purpose of modeling below, encode adenomyosis presence as an indicator $A$, where $A=1$ if present and $A=0$ if absent.\n\nClinical and imaging findings for this patient:\n- Peritoneal implants:\n  - Left pelvic peritoneum: superficial plaque measuring $1.8$ cm.\n  - Right ovarian fossa peritoneum: deep nodule measuring $0.7$ cm.\n- Ovarian implants:\n  - Right ovary: endometrioma measuring $4.2$ cm (deep ovarian lesion).\n  - Left ovary: superficial implant measuring $0.4$ cm.\n- Adhesions:\n  - No adnexal adhesions involving ovaries or fallopian tubes. Tubes are mobile.\n  - Posterior cul-de-sac is partially obliterated by fibrotic bands.\n- Deep infiltrating disease (for Enzian compartments):\n  - Rectovaginal septum: firm nodule measuring $1.2$ cm.\n  - Right uterosacral ligament: deep nodule measuring $0.8$ cm.\n  - Rectum and sigmoid: no infiltration identified.\n- Uterus:\n  - MRI shows junctional zone thickening of $14$ mm with globular uterine enlargement, consistent with adenomyosis.\n\nEpidemiologic prediction model for $1$-year spontaneous conception probability:\n- Let $s$ be the r-ASRM stage as an integer in $\\{1,2,3,4\\}$.\n- Let $a,b,c$ be the Enzian size grades for compartments A, B, and C, each in $\\{0,1,2,3\\}$.\n- Let $\\Sigma = a+b+c$.\n- Let $A$ be the adenomyosis indicator as defined above.\n- The predicted probability $p$ is given by the logistic function\n$$\np \\;=\\; \\frac{1}{1 + \\exp\\!\\big( - \\big( \\alpha \\;-\\; \\beta\\,s \\;-\\; \\gamma\\,\\Sigma \\;-\\; \\delta\\,A \\big) \\big)} \\,,\n$$\nwith parameters $\\alpha = 0.8$, $\\beta = 0.5$, $\\gamma = 0.2$, and $\\delta = 0.6$.\n\nTasks:\n- Using the definitions above, compute the total r-ASRM score $S$ from the findings and determine the r-ASRM stage $s$.\n- Assign the Enzian grades $a$, $b$, and $c$, and compute $\\Sigma$.\n- Encode adenomyosis as $A$ given the imaging.\n- Compute $p$ using the model above. Round your final numerical answer for $p$ to four significant figures. Express the final answer as a decimal fraction with no unit or percentage sign.", "solution": "The problem is valid as it is scientifically grounded in standard clinical classifications and a conventional epidemiologic model, well-posed with all necessary data provided, and objective in its language. We will proceed with a step-by-step computation.\n\nThe first task is to compute the total revised American Society for Reproductive Medicine (r-ASRM) score, denoted by $S$, and determine the corresponding stage, $s$. The score is the sum of points from implants and adhesions.\n\nThe implant points are calculated as follows:\n- Left pelvic peritoneum: This is a superficial lesion measuring $1.8$ cm. According to the scoring rules for superficial peritoneal implants, a size between $1$ cm and $3$ cm corresponds to $2$ points.\n- Right ovarian fossa peritoneum: This is a deep nodule measuring $0.7$ cm. For deep peritoneal implants, a size less than $1$ cm corresponds to $2$ points.\n- Right ovary: This is an endometrioma (deep ovarian lesion) measuring $4.2$ cm. For deep ovarian implants, a size greater than $3$ cm corresponds to $20$ points.\n- Left ovary: This is a superficial implant measuring $0.4$ cm. For superficial ovarian implants, a size less than $1$ cm corresponds to $1$ point.\n\nThe total score for implants is the sum of these points:\n$$S_{\\text{implants}} = 2 + 2 + 20 + 1 = 25$$\n\nThe adhesion points are calculated as follows:\n- Adnexal adhesions involving ovaries and fallopian tubes are absent, contributing $0$ points.\n- The posterior cul-de-sac has partial obliteration, which corresponds to $4$ points.\n\nThe total score for adhesions is:\n$$S_{\\text{adhesions}} = 0 + 4 = 4$$\n\nThe total r-ASRM score $S$ is the sum of implant and adhesion scores:\n$$S = S_{\\text{implants}} + S_{\\text{adhesions}} = 25 + 4 = 29$$\n\nNext, we determine the r-ASRM stage $s$. The staging cutoffs are: Stage I ($1$–$5$ points), Stage II ($6$–$15$ points), Stage III ($16$–$40$ points), and Stage IV ($>40$ points). Since $S = 29$, the patient's endometriosis is Stage III. The corresponding integer value is $s=3$.\n\nThe second task is to assign the Enzian grades for deep endometriosis and compute their sum $\\Sigma$.\n- Compartment A (vagina and rectovaginal septum): There is a nodule measuring $1.2$ cm. Since the size is between $1$ cm and $3$ cm, the grade is $2$. Thus, $a=2$.\n- Compartment B (uterosacral ligaments and pelvic sidewall): There is a nodule measuring $0.8$ cm. Since the size is less than $1$ cm, the grade is $1$. Thus, $b=1$.\n- Compartment C (rectum and sigmoid colon): There is no infiltration. The grade is $0$. Thus, $c=0$.\n\nThe sum $\\Sigma$ is:\n$$\\Sigma = a + b + c = 2 + 1 + 0 = 3$$\n\nThe third task is to encode the presence of adenomyosis. The MRI findings are consistent with adenomyosis. Therefore, according to the problem definition, the adenomyosis indicator is $A=1$.\n\nThe final task is to compute the $1$-year spontaneous conception probability $p$ using the provided logistic model:\n$$p = \\frac{1}{1 + \\exp\\!\\big( - \\big( \\alpha - \\beta s - \\gamma \\Sigma - \\delta A \\big) \\big)}$$\nThe given parameters are $\\alpha = 0.8$, $\\beta = 0.5$, $\\gamma = 0.2$, and $\\delta = 0.6$. We substitute our calculated values: $s=3$, $\\Sigma=3$, and $A=1$.\n\nFirst, we compute the argument of the exponential function, which we denote as $Z$:\n$$Z = \\alpha - \\beta s - \\gamma \\Sigma - \\delta A$$\n$$Z = 0.8 - (0.5)(3) - (0.2)(3) - (0.6)(1)$$\n$$Z = 0.8 - 1.5 - 0.6 - 0.6$$\n$$Z = 0.8 - 2.7 = -1.9$$\n\nNow we substitute this value back into the probability formula:\n$$p = \\frac{1}{1 + \\exp(-Z)} = \\frac{1}{1 + \\exp(-(-1.9))} = \\frac{1}{1 + \\exp(1.9)}$$\n\nTo obtain the numerical value, we compute $\\exp(1.9) \\approx 6.685894...$.\n$$p = \\frac{1}{1 + 6.685894...} = \\frac{1}{7.685894...} \\approx 0.130107...$$\n\nThe problem requires the final answer to be rounded to four significant figures. The first four significant figures are $1$, $3$, $0$, and $1$. The fifth digit is $0$, so we do not round up.\n$$p \\approx 0.1301$$", "answer": "$$\\boxed{0.1301}$$", "id": "4319949"}, {"introduction": "Beyond anatomical staging, modern pathology leverages molecular markers to predict disease behavior and guide therapy. For hormone-sensitive conditions like endometriosis, the balance between estrogen receptor (ER) and progesterone receptor (PR) expression, along with the lesion's proliferative activity, can forecast its response to treatment. In this practice, you will construct quantitative indices from immunohistochemistry (IHC) data to create a 'Progestin Responsiveness Score,' learning how to bridge the gap between microscopic findings and personalized medicine. [@problem_id:4319684]", "problem": "A 36-year-old patient with chronic pelvic pain undergoes laparoscopic excision of a peritoneal implant that is histologically consistent with endometriosis, and magnetic resonance imaging suggests coexisting adenomyosis. Immunohistochemistry (IHC) is performed on the excised endometriotic tissue for Estrogen Receptor (ER), Progesterone Receptor (PR), and Ki-67 (a proliferation marker). The Histologic score (H-score) for each marker is reported on the standard scale from $0$ to $300$ as follows: $H_{\\mathrm{ER}} = 210$, $H_{\\mathrm{PR}} = 120$, and $H_{\\mathrm{Ki67}} = 60$.\n\nUsing only foundational definitions and well-tested facts, construct:\n1. A dimensionless proliferative activity index based on $H_{\\mathrm{Ki67}}$ that reflects the fraction of proliferating cells.\n2. A dimensionless hormonal balance index that increases with PR dominance relative to ER in the lesion, consistent with the idea that progesterone signaling opposes estrogen-driven proliferation.\n\nThen, using first-principles reasoning about receptor-mediated control of proliferation in ectopic endometrium and myometrial glands (adenomyosis), combine these indices into a single dimensionless Progestin Responsiveness Score that increases when progesterone signaling is dominant and decreases when baseline proliferation is high. The combined score must be bounded between $0$ and $1$ and should be constructed from the given $H$-scores by normalization to the $0$–$300$ scale.\n\nCompute the final Progestin Responsiveness Score from the given data and report it as a pure number (no units). Round your final answer to three significant figures.", "solution": "The problem statement is evaluated as scientifically grounded, well-posed, and objective. It provides a set of quantitative data from standard pathological assessments ($H$-scores for ER, PR, and Ki-67) and asks for the construction of biologically meaningful, dimensionless indices based on first principles of endocrinology and cell proliferation. The premises are consistent with established knowledge of endometriosis pathophysiology, where estrogen receptor (ER) signaling drives proliferation and progesterone receptor (PR) signaling is generally opposing. Ki-67 is a standard marker for proliferation. The constraints for the construction of the indices are clear and logically consistent. Therefore, the problem is valid, and a reasoned solution can be constructed.\n\nThe task is to construct three indices in sequence, culminating in a final Progestin Responsiveness Score (PRS). The given data are the Histologic scores (H-scores) on a scale from $0$ to $300$: $H_{\\mathrm{ER}} = 210$, $H_{\\mathrm{PR}} = 120$, and $H_{\\mathrm{Ki67}} = 60$.\n\n**1. Construction of the Proliferative Activity Index ($I_{\\text{prolif}}$)**\n\nThe problem requires a dimensionless proliferative activity index based on $H_{\\mathrm{Ki67}}$ that reflects the fraction of proliferating cells. The $H$-score for Ki-67, $H_{\\mathrm{Ki67}}$, quantifies proliferation on a scale from $0$ (no proliferation) to $300$ (maximum proliferation). A natural and direct way to create a dimensionless index that represents a fractional activity is to normalize the score by its maximum possible value.\n\nWe define the proliferative activity index, $I_{\\text{prolif}}$, as the ratio of the measured $H_{\\mathrm{Ki67}}$ to the maximum possible score, $300$:\n$$I_{\\text{prolif}} = \\frac{H_{\\mathrm{Ki67}}}{300}$$\nThis index is dimensionless and is bounded between $0$ and $1$, satisfying the problem's implicit requirements for such a normalized index.\n\n**2. Construction of the Hormonal Balance Index ($I_{\\text{horm}}$)**\n\nThe problem requires a dimensionless hormonal balance index that increases with PR dominance relative to ER. This is based on the principle that progesterone signaling (via PR) opposes estrogen-driven (via ER) proliferation in endometrial tissue. The index should reflect the balance of power between these two pathways.\n\nTo capture the *relative* dominance of PR, we can consider the fraction of PR expression relative to the total hormonal receptor expression (ER + PR). This formulation has the desirable properties of being dimensionless and bounded. It increases as $H_{\\mathrm{PR}}$ increases or as $H_{\\mathrm{ER}}$ decreases.\n\nWe define the hormonal balance index, $I_{\\text{horm}}$, as:\n$$I_{\\text{horm}} = \\frac{H_{\\mathrm{PR}}}{H_{\\mathrm{ER}} + H_{\\mathrm{PR}}}$$\nThis index ranges from $0$ (when $H_{\\mathrm{PR}} = 0$) to $1$ (when $H_{\\mathrm{ER}} = 0$, assuming $H_{\\mathrm{PR}} > 0$). A value of $0.5$ indicates equal expression levels ($H_{\\mathrm{PR}} = H_{\\mathrm{ER}}$). This construction effectively models the concept of PR dominance. Note that if both $H_{\\mathrm{ER}}$ and $H_{\\mathrm{PR}}$ were $0$, the index would be undefined, but this is biologically unlikely in endometriosis and not the case with the given data.\n\n**3. Construction of the Progestin Responsiveness Score (PRS)**\n\nThe final task is to combine these two indices into a single dimensionless Progestin Responsiveness Score (PRS) that is bounded between $0$ and $1$. The PRS must increase with PR dominance (i.e., increase with $I_{\\text{horm}}$) and decrease as baseline proliferation increases (i.e., decrease with $I_{\\text{prolif}}$).\n\nA high PRS should indicate a high likelihood of a favorable response to progestin therapy. This requires two conditions to be met simultaneously: the tissue must have a hormonal receptor profile favorable to progesterone action (high $I_{\\text{horm}}$), and it must not be 'runaway' or overly proliferative at baseline (low $I_{\\text{prolif}}$). A multiplicative model captures this dual dependency effectively.\n\nWe can model the \"lack of proliferation\" with the term $(1 - I_{\\text{prolif}})$. This term is $1$ when proliferation is zero ($I_{\\text{prolif}} = 0$) and $0$ when proliferation is maximal ($I_{\\text{prolif}} = 1$).\n\nWe can then define the PRS as the product of the hormonal balance index and this \"lack of proliferation\" term:\n$$\\text{PRS} = I_{\\text{horm}} \\times (1 - I_{\\text{prolif}})$$\nThis construction meets all requirements:\n- It is dimensionless as it's a product of dimensionless quantities.\n- Since $0 \\le I_{\\text{horm}} \\le 1$ and $0 \\le (1 - I_{\\text{prolif}}) \\le 1$, their product PRS is also bounded between $0$ and $1$.\n- PRS is directly proportional to $I_{\\text{horm}}$, so it increases with PR dominance.\n- PRS is proportional to $(1-I_{\\text{prolif}})$, so it decreases as $I_{\\text{prolif}}$ increases.\n\n**Calculation**\n\nNow, we compute the value of the PRS using the provided data: $H_{\\mathrm{ER}} = 210$, $H_{\\mathrm{PR}} = 120$, and $H_{\\mathrm{Ki67}} = 60$.\n\nFirst, calculate the component indices:\n$$I_{\\text{prolif}} = \\frac{H_{\\mathrm{Ki67}}}{300} = \\frac{60}{300} = \\frac{1}{5} = 0.2$$\n$$I_{\\text{horm}} = \\frac{H_{\\mathrm{PR}}}{H_{\\mathrm{ER}} + H_{\\mathrm{PR}}} = \\frac{120}{210 + 120} = \\frac{120}{330} = \\frac{12}{33} = \\frac{4}{11}$$\n\nNext, combine them to find the PRS:\n$$\\text{PRS} = I_{\\text{horm}} \\times (1 - I_{\\text{prolif}}) = \\frac{4}{11} \\times \\left(1 - 0.2\\right) = \\frac{4}{11} \\times 0.8 = \\frac{4}{11} \\times \\frac{4}{5} = \\frac{16}{55}$$\n\nFinally, we convert this fraction to a decimal and round to three significant figures as requested.\n$$\\text{PRS} = \\frac{16}{55} \\approx 0.290909...$$\nRounding to three significant figures gives $0.291$.", "answer": "$$\\boxed{0.291}$$", "id": "4319684"}, {"introduction": "Understanding the causes and risk factors of a disease is as important as diagnosing it, requiring skills in epidemiology. This problem simulates a case-control study to investigate potential risk factors for endometriosis, using a hypothetical but illustrative dataset. You will learn to calculate and interpret odds ratios and, more importantly, to grapple with the critical concepts of confounding and effect modification, which are vital for critically evaluating medical literature and understanding the true relationships between an exposure and a disease. [@problem_id:4319783]", "problem": "A gynecologic pathology team is investigating the association between early menarche and surgically confirmed endometriosis within a hospital-based case–control study. Early menarche is defined as age at menarche $\\leq 11$ years. Smoking is hypothesized to be related both to early menarche and to endometriosis via hormonal milieu and inflammatory signaling. Because smoking could distort the observed association between early menarche and endometriosis, the team stratifies the data by smoking status at the reference time and seeks an adjusted estimate for the effect of early menarche.\n\nYou are provided the following $2 \\times 2$ data within each smoking stratum:\n\nNon-smokers:\n- Cases with early menarche: $75$\n- Cases without early menarche: $100$\n- Controls with early menarche: $50$\n- Controls without early menarche: $200$\n\nSmokers:\n- Cases with early menarche: $96$\n- Cases without early menarche: $80$\n- Controls with early menarche: $80$\n- Controls without early menarche: $100$\n\nUsing only core definitions of odds, odds ratio, and stratified pooling, do the following:\n- Compute the crude odds ratio for early menarche and endometriosis ignoring smoking.\n- Compute the stratum-specific odds ratios by smoking status.\n- Compute the Mantel–Haenszel pooled odds ratio for early menarche on endometriosis controlling for smoking.\n- Based solely on these patterns, state whether the data are consistent with confounding by smoking, effect modification by smoking, both, or neither, and justify qualitatively.\n\nFor grading, report only the Mantel–Haenszel pooled odds ratio as your final numeric answer. Express it as a unitless number rounded to four significant figures.", "solution": "The problem is valid as it is scientifically grounded in standard epidemiological principles, well-posed with all necessary data for calculation, and objective in its presentation. We can proceed with the analysis.\n\nFirst, we establish the notation for a $2 \\times 2$ table for a case-control study, stratified by a third variable. Let the strata be indexed by $i$, where $i=1$ corresponds to non-smokers and $i=2$ corresponds to smokers. The exposure is early menarche, and the outcome is endometriosis.\n\nFor each stratum $i$, the data are organized as follows:\n- $a_i$: Cases with the exposure (early menarche)\n- $b_i$: Controls with the exposure (early menarche)\n- $c_i$: Cases without the exposure\n- $d_i$: Controls without the exposure\n- $n_i = a_i + b_i + c_i + d_i$: Total subjects in stratum $i$\n\nThe provided data are:\nFor non-smokers (stratum $i=1$):\n- $a_1 = 75$\n- $b_1 = 50$\n- $c_1 = 100$\n- $d_1 = 200$\n- $n_1 = 75 + 50 + 100 + 200 = 425$\n\nFor smokers (stratum $i=2$):\n- $a_2 = 96$\n- $b_2 = 80$\n- $c_2 = 80$\n- $d_2 = 100$\n- $n_2 = 96 + 80 + 80 + 100 = 356$\n\n### Crude Odds Ratio\nTo compute the crude odds ratio ($OR_{crude}$), we first collapse the data into a single $2 \\times 2$ table, ignoring the smoking status.\n- Total cases with early menarche, $a = a_1 + a_2 = 75 + 96 = 171$\n- Total controls with early menarche, $b = b_1 + b_2 = 50 + 80 = 130$\n- Total cases without early menarche, $c = c_1 + c_2 = 100 + 80 = 180$\n- Total controls without early menarche, $d = d_1 + d_2 = 200 + 100 = 300$\n\nThe odds ratio is the ratio of the odds of exposure among cases to the odds of exposure among controls.\n$$ OR_{crude} = \\frac{\\text{Odds(Exposure | Cases)}}{\\text{Odds(Exposure | Controls)}} = \\frac{a/c}{b/d} = \\frac{ad}{bc} $$\nSubstituting the values from the collapsed table:\n$$ OR_{crude} = \\frac{171 \\times 300}{130 \\times 180} = \\frac{51300}{23400} = \\frac{513}{234} = \\frac{57}{26} \\approx 2.1923 $$\n\n### Stratum-Specific Odds Ratios\nNext, we compute the odds ratio within each stratum. The formula for the stratum-specific odds ratio, $OR_i$, is:\n$$ OR_i = \\frac{a_i d_i}{b_i c_i} $$\n\nFor non-smokers (stratum $i=1$):\n$$ OR_1 = \\frac{a_1 d_1}{b_1 c_1} = \\frac{75 \\times 200}{50 \\times 100} = \\frac{15000}{5000} = 3.0 $$\n\nFor smokers (stratum $i=2$):\n$$ OR_2 = \\frac{a_2 d_2}{b_2 c_2} = \\frac{96 \\times 100}{80 \\times 80} = \\frac{9600}{6400} = \\frac{96}{64} = \\frac{3}{2} = 1.5 $$\n\n### Mantel–Haenszel Pooled Odds Ratio\nThe Mantel–Haenszel pooled odds ratio, $OR_{MH}$, provides an adjusted estimate of the association, controlling for the variable used for stratification (smoking). It is a weighted average of the stratum-specific odds ratios. The formula is:\n$$ OR_{MH} = \\frac{\\sum_{i=1}^{k} \\frac{a_i d_i}{n_i}}{\\sum_{i=1}^{k} \\frac{b_i c_i}{n_i}} $$\nwhere $k$ is the number of strata, which is $2$ in this problem.\n\nWe calculate the numerator and denominator contributions from each stratum:\nFrom stratum $1$ (non-smokers):\n- Numerator contribution: $\\frac{a_1 d_1}{n_1} = \\frac{75 \\times 200}{425} = \\frac{15000}{425}$\n- Denominator contribution: $\\frac{b_1 c_1}{n_1} = \\frac{50 \\times 100}{425} = \\frac{5000}{425}$\n\nFrom stratum $2$ (smokers):\n- Numerator contribution: $\\frac{a_2 d_2}{n_2} = \\frac{96 \\times 100}{356} = \\frac{9600}{356}$\n- Denominator contribution: $\\frac{b_2 c_2}{n_2} = \\frac{80 \\times 80}{356} = \\frac{6400}{356}$\n\nNow we sum these contributions to find the pooled odds ratio:\n$$ OR_{MH} = \\frac{\\frac{15000}{425} + \\frac{9600}{356}}{\\frac{5000}{425} + \\frac{6400}{356}} $$\nTo compute this precisely, we use a common denominator for the terms in the main fraction's numerator and denominator respectively:\n$$ OR_{MH} = \\frac{ \\frac{15000 \\times 356 + 9600 \\times 425}{425 \\times 356} }{ \\frac{5000 \\times 356 + 6400 \\times 425}{425 \\times 356} } = \\frac{15000 \\times 356 + 9600 \\times 425}{5000 \\times 356 + 6400 \\times 425} $$\n$$ OR_{MH} = \\frac{5340000 + 4080000}{1780000 + 2720000} = \\frac{9420000}{4500000} = \\frac{942}{450} = \\frac{471}{225} = \\frac{157}{75} $$\nAs a decimal, this is:\n$$ OR_{MH} = \\frac{157}{75} \\approx 2.09333... $$\nRounding to four significant figures, we get $2.093$.\n\n### Assessment of Confounding and Effect Modification\nBased on the computed values, we can assess the roles of confounding and effect modification.\n\n**Effect Modification:** Effect modification (or interaction) is present if the measure of association (the odds ratio) between the exposure and outcome differs across levels of a third variable.\n- $OR_{non-smokers} = 3.0$\n- $OR_{smokers} = 1.5$\nThe odds ratio for the association between early menarche and endometriosis is substantially different for non-smokers ($3.0$) compared to smokers ($1.5$). This difference in the magnitude of the effect across strata is the definition of effect modification. The effect appears to be stronger in non-smokers.\n\n**Confounding:** Confounding is present if a third variable distorts the observed association between an exposure and an outcome. A key indicator of confounding is a difference between the crude effect measure and the adjusted (pooled) effect measure.\n- $OR_{crude} \\approx 2.192$\n- $OR_{MH} \\approx 2.093$\nThe crude odds ratio ($2.192$) is different from the Mantel-Haenszel adjusted odds ratio ($2.093$). The crude estimate overstates the association compared to the adjusted estimate. This discrepancy indicates the presence of confounding by smoking. For confounding to exist, smoking must be associated with both early menarche (exposure) and endometriosis (outcome). The data support these associations.\n\n**Conclusion:** The data patterns are consistent with the presence of **both confounding and effect modification** by smoking. The stratum-specific odds ratios are different from each other, indicating effect modification. The crude odds ratio is different from the pooled, adjusted odds ratio, indicating confounding.", "answer": "$$\\boxed{2.093}$$", "id": "4319783"}]}